PATROCINADORES CORPORATIVOS
Actividades avaladas SETH
Simposio "High purity VWF/FVIII complex concentrates: current role and perspectives"
10 de marzo de 2007 - Roma, Italia
Simposio internacional que tratará sobre las estrategias terapéuticas en EVW y la actualización den temas relacionados con incidencia de inhibidores y su tratamiento en HA.
Responsable científico
Eva Bastida (Medical Marketing)
Esta dirección de correo electrónico está protegida contra spambots. Usted necesita tener Javascript activado para poder verla.
C/ de la Marina, 16-18 planta 30
08005 Barcelona - España
Tel. +34 935 710 500
Responsables organizativos
Isidre Torras (Dir. Marketing)
Esta dirección de correo electrónico está protegida contra spambots. Usted necesita tener Javascript activado para poder verla.
Joana Sabat (Product Manager Coagulación)
Esta dirección de correo electrónico está protegida contra spambots. Usted necesita tener Javascript activado para poder verla.
C/ de la Marina, 16-18 planta 30
08005 Barcelona - España
Tel. +34 935 710 500
| Scientific Program | |
| 08:45 | Opening remarks PM Mannucci New approaches in the management of Von Willebrand’s disease Chariman: F. Rodeghiero (Vicenza) |
| 09:00 | Diagnosis and treatment of von Willebrand disease: an update C. Kessler (Washinghton) |
| 09:30 | Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand’s disease: the PROWILL study AB. Federici (Milan) |
| 10:00 | Fanhdi efficacy and safety in von Willebrand’s disease: prospective international study results F. Hernández (Madrid) |
| 10:30 | Discussion |
| 10:45 | Coffee Break Present safety issues in clotting factor concentrates: Chairman: L. Aledort (New York) |
| 11:00 | Safety record of plasmaderivatives clotting factors L. Aledort (New York) |
| 11:30 | Safety procedures of Grifols coagulation factors JI. Jorquera (Barcelona) |
| 12:00 | Incidence of inhibitors development in hemophilia A: the role of VWF/FVIII concentrates. W. Kreutz (Frankfurt) |
| 12:30 | Discussion |
| 12:45 | LUNCH VWF/FVIII concentrates and the Hemophilia patient with inhibitors Chairmen: C. Hay (Manchester) |
| 14:45 | Inhibitors in hemophilia A: current management and open issues S. Haya (Valencia) |
| 15:15 | The role of VWF in FVIII concentrates immunogenicity. S. Kaveri (Paris) |
| 15:45 | FVIII inhibitors onset in PUPS: recombinant vs. VWF/FVIII complex. The SIPPET study PM. Mannucci (Milan) |
| 16:15 | VWF/FVIII concentrates in high risk immunetolerance: the RESIST study A. Gringeri (Milan) |
| 16:45 | VWF/FVIII complex and the management of patient with inhibitors from laboratory to clinical practice. E Berntorp (Malmo) |
| 17:15 | Discussion |
| 17:30 | PM. Mannucci: Closing remarks |